Why We’ve Got All Eyes on Tiziana Life Sciences (Nasdaq: TLSA) Right Now

*Sponsored Market Crux Announces Its Next Potential Breakout Idea! See Why Tiziana Life Sciences (Nasdaq: TLSA) is Taking the Top Spot On Our Watchlist Right Now… Tiziana Life Sciences (Nasdaq: TLSA) Comes Backed By  Several Potential Catalysts Like: The neurodegenerative disease market is projected to climb from $52B in 2024 to over $102B by 2034, creating immense demand for innovation like Foralumab. Tiziana (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView, pointing to heightened attention from the public. Foralumab, the first fully human anti-CD3 antibody delivered intranasally, is transforming how complex diseases are addressed. The first moderate Alzheimer’s patient dosed at Brigham and Women’s Hospital marks a vital step forward in tackling this devastating condition. Get the details on why (TLSA) is taking center stage today… January 23, 2025 Dear Reader, What if the key to solving some of medicine’s most challenging diseases lay in a revolutionary approach that defies traditional methods? Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is doing exactly that—breaking new ground with innovative solutions that could change how complex conditions are treated. Just yesterday, Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView’s technical indicator tool using the 30-minute time frame, pointing to increasing momentum potential around the company. As a clinical-stage biopharmaceutical company, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is introducing transformational dr-ug delivery technologies designed to reshape the future of immunotherapy. Their efforts come at a pivotal moment. The global neurodegenerative disease market is forecasted to grow from $52B in 2024 to over $102B by 2034, driven by an aging population, advancements in precision medicine, and a growing need for effective therapies to combat conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis.  And according to Benzinga, insiders own over 72% of the company’s shares—what do they know? Could it be the groundbreaking potential of their intranasal therapy, the rapidly growing neurodegenerative disease market, or the promising results from their recent clinical trials? Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s focus on intranasal Foralumab places it in a strong position to address these urgent and rapidly expanding needs. At the forefront of their pipeline is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development. With the potential to improve efficacy, safety, and tolerability compared to traditional intravenous treatments, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is turning heads for all the right reasons. Let’s explore what sets this company apart. Recent Developments Promising Results for Metabolic Disorders Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced findings that its nasal anti-CD3 therapy mitigates side effects commonly associated with GLP-1 agonist discontinuation, such as muscle loss and bone density issues. This development highlights the potential of nasal anti-CD3 in sustaining tissue homeostasis and improving patient outcomes in metabolic and age-related diseases. Foralumab Featured in Nature Reviews Neurology A review article published in Nature Reviews Neurology highlighted Foralumab’s therapeutic potential across multiple neurodegenerative diseases, including Alzheimer’s, multiple sclerosis, ALS, and Parkinson’s. The publication underscored the role of intranasal delivery in dampening microglial activation—a critical factor in disease progression. Alzheimer’s Clinical Trial Milestone Achieved The company dosed its first patient with moderate Alzheimer’s disease using intranasal Foralumab at Brigham and Women’s Hospital in Boston. This innovative therapy targets neuroinflammation by modulating microglial cells, a novel approach distinct from amyloid and tau protein-focused therapies. Expansion of SPMS Clinical Trial to Prestigious Institutions Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) recently expanded its Phase 2 clinical trial for non-active secondary progressive multiple sclerosis (SPMS) to include leading U.S. medical institutions such as Yale University, Johns Hopkins University, and Cornell University. The expanded trial reflects Tiziana’s commitment to advancing research in SPMS, a condition with no FDA-approved therapeutic options. The use of a centralized PET imaging site ensures data consistency and robust trial outcomes. These updates showcase Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s relentless focus on addressing significant unmet medical needs with groundbreaking solutions. Redefining Treatment with Intranasal Foralumab At the heart of Tiziana’s efforts is Foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical trials. Administered intranasally, this therapy doesn’t just break the mold—it demolishes it. This innovative delivery system allows Foralumab to modulate the immune system efficiently while crossing the blood-brain barrier to target neuroinflammation directly. The potential benefits span multiple conditions: Secondary Progressive Multiple Sclerosis (SPMS): Characterized by a progressive loss of neurological function, SPMS remains one of the most challenging forms of multiple sclerosis to address. Alzheimer’s Disease (AD): By modulating microglial activity—key drivers of neuroinflammation—Foralumab offers a fresh approach distinct from conventional amyloid-targeting treatments. The Focus on Neuroinflammatory and Neurodegenerative Conditions Tiziana has zeroed in on areas with substantial clinical challenges.  Here’s a closer look at why its work matters: SPMS Progress: In an expanded access program, participants demonstrated improved fatigue levels and reduced brain inflammation, as measured by microglial activation. These are significant outcomes in a condition where effective therapies are limited. Alzheimer’s Disease: Preclinical studies have shown Foralumab’s ability to alleviate inflammation in the brain. With Phase 2 trials beginning in 2024, the therapy is positioned to offer a novel approach that complements existing treatments. What Sets Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Apart A Unique Approach to Delivery: By choosing an intranasal delivery method, Tiziana ensures precise targeting of neuroinflammation with minimal systemic side effects. This is a pivotal advantage in managing chronic neurological conditions. Robust Data Supporting Its Platform: Published findings in the Proceedings of the National Academy of Sciences underscore Foralumab’s impact across multiple conditions, including SPMS and a recent global pan-demic. These results highlight its ability to regulate T-cell activity and reduce inflammation effectively. Experienced Leadership Driving Innovation: With Executive Chairman and Founder Gabriele Cerrone at the helm, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) benefits from a leadership team with deep expertise in dr-ug development. Cerrone’s history of guiding biotech firms to major milestones reinforces confidence in Tiziana’s trajectory. Potential Beyond the Current Pipeline: While SPMS and Alzheimer’s are the primary focuses, Foralumab’s mechanism of action points to broader applications across inflammatory and neurodegenerative diseases, setting the stage for further advancements. Key Milestones to Watch SPMS Phase 2a Progress: Ongoing trials are evaluating Foralumab’s efficacy and safety, with early data showing promising outcomes in reducing inflammation and improving symptoms. Alzheimer’s Phase 2 Launch: This trial will explore the therapy’s effects on microglial activity, a significant contributor to disease progression in Alzheimer’s. Expanded Research: Tiziana continues to explore additional indications where its intranasal anti-CD3 platform can make a meaningful difference. A Company Worth Watching Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is positioning itself as a leader in innovative therapies for neuroinflammatory and neurodegenerative diseases.  With groundbreaking science, proven leadership, and a clear focus on addressing critical medical challenges, this is a company making real strides in areas where effective solutions are desperately needed.  Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s work stands as a testament to what’s possible when science and ingenuity converge. 7 Reasons Why Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Deserves a Spot on Your Radar… 1. Neurodegenerative Market Poised for Growth: With projections to grow from $52B in 2024 to over $102B by 2034, demand for innovative treatments like Foralumab is set to surge. 2. Strong Bullish Signals Detected: Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView’s 30-minute timeframe yesterday, hinting at the potential of a growing interest from the public. 3. Innovative Intranasal Technology: Foralumab, the first fully human anti-CD3 monoclonal antibody delivered intranasally, offers a novel and precise approach to treating complex conditions. 4. Credibility Boost from Leading Institutions: Yale, Johns Hopkins, and Cornell have joined Phase 2 trials for SPMS, amplifying Foralumab’s potential impact on secondary progressive multiple sclerosis. 5. Alzheimer’s Research Breakthrough: The first patient with moderate Alzheimer’s disease has been dosed at Brigham and Women’s Hospital, marking a critical milestone in addressing this urgent unmet need. 6. Recognition in Scientific Leadership: Foralumab has been featured in Nature Reviews Neurology, spotlighting its potential in conditions like multiple sclerosis, Alzheimer’s, ALS, and Parkinson’s. 7. Expanding Applications Beyond Neurology: Nasal anti-CD3 therapy is also showing promise in metabolic conditions, addressing challenges associated with GLP-1 agonist discontinuation, such as muscle and bone loss. With its innovative intranasal delivery system, recognition in Nature Reviews Neurology, and advancements in SPMS and Alzheimer’s research, Tiziana Life Sciences (Nasdaq: TLSA) is quickly becoming a company to watch closely.  Consider adding (TLSA) to your radar today.   We have all eyes on (TLSA) right now. I’ll follow up with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/23/2025 and ending on 01/23/2025 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, Headline Media LLC has been paid six thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.Neither Headline Media LLC, TD Media LLC and their members own shares of (TLSA:US). Please see important disclosure information here: https://marketcrux.com/disclosure/tlsa/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice